🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 5 of 173

  1. US 12280088

    Dry powder formulation of caveolin-1 peptides and methods of use thereof

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12281078

    Quinoline cGAS antagonist compounds

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12280089

    Dry powder formulation of caveolin-1 peptides and methods of use thereof

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12281105

    Contraceptive compounds and methods

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12281021

    System and method for making boron oxide nanoparticles

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12281327

    Lymphohematopoietic engineering using CAS9 base editors

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12280057

    Vasoactive topical compound to affect tissue blood flow, reduce tissue necrosis and promote healing

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12275781

    Monoclonal antibodies against MHC-bound human dickkopf-1 peptides and uses thereof

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12275957

    Next generation designer liver organoids and their methods of preparation and use

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12274759

    Affibody proteins specific for B7-H3 (CD276)

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12275685

    Oligo-benzamide analogs and their use in cancer treatment

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12275966

    Genetically engineered cells

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12274725

    Zika virus strains for treatment of glioma

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12275964

    Variant type V CRISPR/Cas effector polypeptides and methods of use thereof

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12268777

    Compositions and methods for treating eosinophilic disorders

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12269805

    Inhibitors of platelet function and methods for use of the same

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12269887

    Anti-canine CD16 polypeptides, anti-canine CD64 polypeptides, compositions including same, and methods of using

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12268678

    Formulations of hydroxypyridonate actinide/lanthanide decorporation agents

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12268683

    Compounds and methods for synergistic activation of M channels

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12270080

    NcRNA and uses thereof

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12270050

    Human T cell derived from T cell-derived induced pluripotent stem cell and methods of making and using

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12264336

    Platform for generating safe cell therapeutics

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12263243

    Templated open flocs of anisotropic particles for enhanced pulmonary delivery

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12263165

    Small molecule inhibitors of cancer stem cells and mesenchymal cancer types

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12263250

    Nanofiber segments and methods of use thereof

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12264158

    Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12263156

    Use of small molecule inhibitors of the BfrB:Bfd interaction in biofilms

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12257235

    Methods and materials for using ruminococcus gnavus or clostridium sporogenes to treat gastrointestinal disorders

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12257261

    Preparation of preliposomal Annamycin lyophilizate

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12258370

    Betulastatin compounds

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12257326

    TCO conjugates and methods for delivery of therapeutic agents

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12257278

    Methods of treating cancer with TNF expressing myxoma virus

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12257262

    Method of reconstituting liposomal annamycin

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12257306

    Antiviral prodrugs and nanoformulations thereof

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12257352

    Compositions and methods for delivery of biomacromolecule agents

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12257266

    Stem cell-derived exosomes for the treatment of corneal scarring

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12257302

    Universal vaccine platform

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12258425

    Peptide compositions and methods of use

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12258575

    RNA-guided nucleic acid modifying enzymes and methods of use thereof

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12257325

    Chelating platform for delivery of radionuclides

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12258612

    Random heteropolymers preserve protein function in foreign environments

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12251397

    Cross-linked hyaluronic acids and combinations with PRP/BMC

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12252746

    Anti-CD46 antibodies and methods of use

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12251478

    Bioactive polymeric dressing for accelerated wound closure

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12252480

    Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1H-1,2,3-triazole-4-carboxamide

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12252714

    Halogenation of complex organic compounds

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12252515

    Compositions and methods for inhibiting Wnt signaling

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12251379

    Methods of inhibiting formation of alpha synuclein aggregates

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.